PREOPERATIVE INTRAPERITONEAL CHEMOTHERAPY FOR GASTRIC-CANCER, WITH SPECIAL REFERENCE TO DELAYED PERITONEAL COMPLICATIONS

被引：12

作者：

ADACHI, W

KOIKE, S

RAFIQUE, M

KAJIKAWA, S

KANEKO, G

KURODA, T

IIDA, F

ISHII, K

机构：

[1] Department of Surgery, Shinshu University School of Medicine, Nagano, 390, 3-1-1 Asahi, Matsumoto

[2] Central Clinical Laboratories, Shinshu University School of Medicine, Nagano, 390, 3-1-1 Asahi, Matsumoto

来源：

SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1995年 / 25卷 / 05期

关键词：

GASTRIC CANCER; INTRAPERITONEAL CHEMOTHERAPY; INTESTINAL OBSTRUCTION; PERITONITIS; ADHESION;

D O I：

10.1007/BF00311815

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Preoperative intraperitoneal (IP) chemotherapy was performed in 23 patients with gastric malignancies to inhibit peritoneal recurrence. Cis-diamminedichloroplatinum (CDDP) and mitomycin C (MMC) were administered intraperitoneally 3 days prior to surgery, at which time a very viscid peritoneum and mucinous intraperitoneal fluid were found in 100% and 83% of the patients, respectively. Inflammatory changes were microscopically observed in the subserosal layer of the resected stomachs and in the intraperitoneal fluid, but degenerative changes characteristic of cancer cells could not be seen. The 3-year survival rate of the stage III patients was 55.6%, and peritoneal recurrence was found in three of six patients with recurrence. Extensive adhesions were found in eight patients (34.8%) as a delayed peritoneal complication, and chronic bowel obstruction resulting from the adhesion developed in five patients (21.7%). Thus, we conclude that the administration of this IP chemotherapy demonstrated no definite antitumor effects or survival benefits, but was frequently associated with delayed peritoneal complications.

引用

页码：396 / 403

页数：8

共 29 条

[11]

The general rules for the gastric cancer study in surgery and pathology. Part II. Histological classification of gastric cancer, Jpn J Surg, 11, pp. 140-145, (1981)

[12]

Fujita H., In vivo distribution of anticancer agents — Methods of Assay, Gan to Kagakuryoho (Jpn J Cancer Chemother), 1, pp. 497-503, (1974)

[13]

Bannister S.J., Chang Y., Sternson L.A., Repta A.J., Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichloro diammineplatinum (II), Clin Chem, 24, pp. 877-880, (1978)

[14]

Nakajima T., Adjuvant chemotherapy for gastric cancer in Japan: Present status and suggestions for rational clinical trials, Jpn J Clin Oncol, 20, pp. 30-42, (1990)

[15]

Leichman L., McDonald B., Dindogru A., Saon M., Vaitkevicius V.K., Cisplatin. An active drug in the treatment of disseminated gastric cancer, Cancer, 53, pp. 18-22, (1984)

[16]

Reichman B., Markman M., Hakes T., Hoskins W., Rubin S., Jones W., Almadrones L., Ochoa M., Chapman D., Saigo P., Lewis J.L., Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma, J Clin Oncol, 7, pp. 1327-1332, (1989)

[17]

Schilsky R.L., Choi K.E., Grayhack J., Grimmer D., Guarnieri C., Fullem L., Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer, J Clin Oncol, 8, pp. 2054-2061, (1990)

[18]

Kano T., Kumashiro R., Masuda H., Tamada R., Inokuchi K., Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection, Jpn J Surg, 13, pp. 112-116, (1983)

[19]

Akiyoshi T., Kawaguchi M., Arinaga S., Miyazaki S., Koba F., Wada T., Tsuji H., Combination chemoimmunotherapy for advanced gastric carcinoma, Jpn J Surg, 14, pp. 185-190, (1984)

[20]

Philips F.S., Schwartz H.S., Sternberg S.S., Pharmacology of mitomycin C. I. Toxicity and pathologic effects, Cancer Res, 20, pp. 1354-1361, (1960)

← 1 2 3 →